

the moving defendant may be rejoined to the action as provided in section 1606 of this title.

**(f) Manufacturer conduct of litigation**

The manufacturer of an implant that is the subject of an action covered under this chapter shall be permitted to conduct litigation on any motion for summary judgment or dismissal filed by a biomaterials supplier who is a defendant under this section on behalf of such supplier if the manufacturer and any other defendant in such action enter into a valid and applicable contractual agreement under which the manufacturer agrees to bear the cost of such litigation or to conduct such litigation.

(Pub. L. 105-230, §6, Aug. 13, 1998, 112 Stat. 1526.)

SECTION REFERRED TO IN OTHER SECTIONS

This section is referred to in sections 1603, 1604, 1606 of this title.

**§ 1606. Subsequent impleader of dismissed biomaterials supplier**

**(a) Impleading of dismissed defendant**

A court, upon motion by a manufacturer or a claimant within 90 days after entry of a final judgment in an action by the claimant against a manufacturer, and notwithstanding any otherwise applicable statute of limitations, may implead a biomaterials supplier who has been dismissed from the action pursuant to this chapter if—

(1) the manufacturer has made an assertion, either in a motion or other pleading filed with the court or in an opening or closing statement at trial, or as part of a claim for contribution or indemnification, and the court finds based on the court's independent review of the evidence contained in the record of the action, that under applicable law—

(A) the negligence or intentionally tortious conduct of the dismissed supplier was an actual and proximate cause of the harm to the claimant; and

(B) the manufacturer's liability for damages should be reduced in whole or in part because of such negligence or intentionally tortious conduct; or

(2) the claimant has moved to implead the supplier and the court finds, based on the court's independent review of the evidence contained in the record of the action, that under applicable law—

(A) the negligence or intentionally tortious conduct of the dismissed supplier was an actual and proximate cause of the harm to the claimant; and

(B) the claimant is unlikely to be able to recover the full amount of its damages from the remaining defendants.

**(b) Standard of liability**

Notwithstanding any preliminary finding under subsection (a) of this section, a biomaterials supplier who has been impleaded into an action covered by this chapter, as provided for in this section—

(1) may, prior to entry of judgment on the claim against it, supplement the record of the proceeding that was developed prior to the

grant of the motion for impleader under subsection (a) of this section; and

(2) may be found liable to a manufacturer or a claimant only to the extent required and permitted by any applicable State or Federal law other than this chapter.

**(c) Discovery**

Nothing in this section shall give a claimant or any other party the right to obtain discovery from a biomaterials supplier at any time prior to grant of a motion for impleader beyond that allowed under section 1605 of this title.

(Pub. L. 105-230, §7, Aug. 13, 1998, 112 Stat. 1528.)

SECTION REFERRED TO IN OTHER SECTIONS

This section is referred to in sections 1603, 1604, 1605 of this title.

**CHAPTER 22—NATIONAL DRUG CONTROL POLICY**

Sec.	
1701.	Definitions.
1702.	Office of National Drug Control Policy.
	(a) Establishment of Office.
	(b) Director and Deputy Directors.
	(c) Access by Congress.
	(d) Office of National Drug Control Policy Gift Fund.
1703.	Appointment and duties of Director and Deputy Directors.
	(a) Appointment.
	(b) Responsibilities.
	(c) National Drug Control Program budget.
	(d) Powers of the Director.
	(e) Personnel detailed to Office.
	(f) Fund control notices.
	(g) Inapplicability to certain programs.
	(h) Construction.
1704.	Coordination with National Drug Control Program agencies in demand reduction, supply reduction, and State and local affairs.
	(a) Access to information.
	(b) Certification of policy changes to Director.
	(c) General Services Administration.
	(d) Accounting of funds expended.
1705.	Development, submission, implementation, and assessment of National Drug Control Strategy.
	(a) Timing, contents, and process for development and submission of National Drug Control Strategy.
	(b) Annual strategy report.
	(c) Performance measurement system.
1706.	High Intensity Drug Trafficking Areas Program.
	(a) Establishment.
	(b) Designation.
	(c) Factors for consideration.
	(d) Use of funds.
1707.	Counter-Drug Technology Assessment Center.
	(a) Establishment.
	(b) Director of Technology.
	(c) Additional responsibilities of the Director of National Drug Control Policy.
	(d) Assistance and support to Office of National Drug control Policy.
1708.	President's Council on Counter-Narcotics.
	(a) Establishment.
	(b) Membership.
	(c) Functions.
	(d) Administration.
1709.	Parents Advisory Council on Youth Drug Abuse.

Sec.

- (a) In general.
- (b) Duties of Council.
- (c) Expenses.
- (d) Authorization of appropriations.
- 1710. Drug interdiction.
  - (a) Definition.
  - (b) Report.
  - (c) Budget process.
- 1711. Authorization of appropriations.
- 1712. Termination of Office of National Drug Control Policy.
  - (a) In general.
  - (b) Exception.
- 1713. Authorization of use of environmentally-approved herbicides to eliminate illicit narcotics crops.

**§ 1701. Definitions**

In this chapter:

**(1) Demand reduction**

The term “demand reduction” means any activity conducted by a National Drug Control Program agency, other than an enforcement activity, that is intended to reduce the use of drugs, including—

- (A) drug abuse education;
- (B) drug abuse prevention;
- (C) drug abuse treatment;
- (D) drug abuse research;
- (E) drug abuse rehabilitation;
- (F) drug-free workplace programs; and
- (G) drug testing.

**(2) Director**

The term “Director” means the Director of National Drug Control Policy.

**(3) Drug**

The term “drug” has the meaning given the term “controlled substance” in section 802(6) of this title.

**(4) Drug control**

The term “drug control” means any activity conducted by a National Drug Control Program agency involving supply reduction or demand reduction.

**(5) Fund**

The term “Fund” means the fund established under section 1702(d) of this title.

**(6) National Drug Control Program**

The term “National Drug Control Program” means programs, policies, and activities undertaken by National Drug Control Program agencies pursuant to the responsibilities of such agencies under the National Drug Control Strategy.

**(7) National Drug Control Program agency**

The term “National Drug Control Program agency” means any agency that is responsible for implementing any aspect of the National Drug Control Strategy, including any agency that receives Federal funds to implement any aspect of the National Drug Control Strategy, but does not include any agency that receives funds for drug control activity solely under the National Foreign Intelligence Program, the Joint Military Intelligence Program or Tactical Intelligence and Related Activities, unless such agency has been designated—

- (A) by the President; or
- (B) jointly by the Director and the head of the agency.

**(8) National Drug Control Strategy**

The term “National Drug Control Strategy” means the strategy developed and submitted to Congress under section 1705 of this title.

**(9) Office**

Unless the context clearly implicates otherwise, the term “Office” means the Office of National Drug Control Policy established under section 1702(a) of this title.

**(10) State and local affairs**

The term “State and local affairs” means domestic activities conducted by a National Drug Control Program agency that are intended to reduce the availability and use of drugs, including—

- (A) coordination and facilitation of Federal, State, and local law enforcement drug control efforts;
- (B) promotion of coordination and cooperation among the drug supply reduction and demand reduction agencies of the various States, territories, and units of local government; and
- (C) such other cooperative governmental activities which promote a comprehensive approach to drug control at the national, State, territory, and local levels.

**(11) Supply reduction**

The term “supply reduction” means any activity of a program conducted by a National Drug Control Program agency that is intended to reduce the availability or use of drugs in the United States and abroad, including—

- (A) international drug control;
- (B) foreign and domestic drug intelligence;
- (C) interdiction; and
- (D) domestic drug law enforcement, including law enforcement directed at drug users.

(Pub. L. 105-277, div. C, title VII, § 702, Oct. 21, 1998, 112 Stat. 2681-670.)

**REPEAL OF SECTION**

*For repeal of section on Sept. 30, 2003, see section 1712 of this title.*

**REFERENCES IN TEXT**

This chapter, referred to in text, was in the original “this title”, meaning title VII of div. C of Pub. L. 105-277, Oct. 21, 1998, 112 Stat. 2681-670, known as Office of National Drug Control Policy Reauthorization Act of 1998, which is classified principally to this chapter. For complete classification of title VII to the Code, see Short Title note set out below and Tables.

**SHORT TITLE**

Pub. L. 105-277, div. C, title VII, § 701, Oct. 21, 1998, 112 Stat. 2681-670, provided that: “This title [enacting this chapter, amending section 1509 of this title, sections 5312 to 5314 of Title 5, Government Organization and Employees, section 1105 of Title 31, Money and Finance, and section 402 of Title 50, War and National Defense] may be cited as the ‘Office of National Drug Control Policy Reauthorization Act of 1998’.”